CER Will Accelerate Copay Incentives In Private Coverage, United Exec Says
The increasing availability of comparative effectiveness data on drug treatments will foster broader use of copay structures that discourage patients from seeking higher cost treatments that offer no real benefit over lower cost drugs, UnitedHealthcare Senior VP-Oncology Lee Newcomer predicted at a conference on CER and personalized medicine held at the National Institutes of Health Oct. 20.
You may also be interested in...
United Healthcare launches pilot program that will eliminate the markup on chemotherapy drugs as an incentive for prescribing.
The new payment innovation center at the Centers for Medicare and Medicaid Services is shaping up as a high-priority program for the agency, as demonstrated by the recent appointment of former Geisinger executive Richard Gilfillan to head the unit.
Both proposals involve legislation that would authorize Medicare Part B to pay for drugs based on the price of the lowest-cost alternative.